Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EXG102-031

Phase 2Biologic

GGuangzhou Jiayin Biotech Ltd

EXG102-031 is one of 2 biologic programs targeting wAMD. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

WamdUnknown status

WamdPhase 2

Unknown status

Competition

Competitive Landscape

1 competitor in Wamd

#DrugCompanyPhaseTrials

AL-001

BBeijing Anlong Biopharmaceutical Co., Ltd.

EXG102-031

GGuangzhou Jiayin Biotech Ltd

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

wAMD2 trials

A Study of EXG102-031 in Participants With wAMD

Unknown status·GGuangzhou Jiayin Biotech Ltd·Phase 1/2·NCT06183814·42 enrolled

A Study of EXG102-031 in Patients With wAMD (Everest)

Active, not recruiting·EExegenesis Bio·Phase 1·NCT05903794·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EXG102-031. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EXG102-031 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EXG102-031. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Jiayin Biotech Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: GGuangzhou Jiayin Biotech Ltd

Related News